Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase 3 study of subcutaneous efgartigimod PH20 in generalized myasthenia gravis
NL-OMON54450Phase 3Completed
- Sponsor
- PPD
- Start
- Aug 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by PPD. Primary endpoint: Long-term safety and tolerability. Started Aug 2021; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON54450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54450.